SecBot SecBot
144 ·Filed Sep 15, 2026

RVMD

Revolution Medicines, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed2mo ago SEC0001294192-26-000005
Actionable Insight • Neutral

Two Form 144 notices filed 2026-09-15 signal insider selling intent at Revolution Medicines. Margaret A. Horn (Officer) intends to sell 29,600 shares (~$4.74M) via RSU vesting. Mark A. Goldsmith (Director) intends to sell 80,000 shares (~$16.74M) from trusts. Combined ~$21.5M in proposed sales. This follows 8 insider sells totaling $4.3M in the past 30 days. The sales are RSU-vesting and trust-related, not open-market discretionary, but the dollar amounts are material relative to recent insider activity. Market cap is $44.0B, so the sales are small relative to company size. Impact: moderate negative tilt, score 4.

DirectionNeutral
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$195.92
T+0 close · Sep 15, 2026 · via day close
Latest settled
−3.82%
T+20 · $188.44 · next T+60 in 23d
Vs SPY
−7.00%
α at T+20
Latest observation
−4.92%
T+41 · FF3 residual α
  1. T+0 · Sep 16 $195.92entry
  2. T+1 · 2mo ago +0.52%α −0.61% · $196.94
  3. T+5 · 8w ago −2.64%α −5.21% · $190.74
  4. T+20 · 5w ago −3.82%α −7.00% · $188.44
  5. T+43 · todayOpen
  6. T+60 · in 23d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two Form 144 notices filed 2026-09-15 signal insider selling intent at Revolution Medicines. Margaret A. Horn (Officer) intends to sell 29,600 shares (~$4.74M) via RSU vesting. Mark A. Goldsmith (Director) intends to sell 80,000 shares (~$16.74M) from trusts. Combined ~$21.5M in proposed sales. This follows 8 insider sells totaling $4.3M in the past 30 days. The sales are RSU-vesting and trust-related, not open-market discretionary, but the dollar amounts are material relative to recent insider activity. Market cap is $44.0B, so the sales are small relative to company size. Impact: moderate negative tilt, score 4.

Financial Impact

Not specified

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (RVMD), Batch item 10001294192-26-000005
Document: 0001294192-26-000005-index.html0001246842-26-000006
Document: 0001294192-26-000005.txt0001294192-26-000005
144 Filing (RVMD), Batch item 40001246842-26-000006
Document: 0001246842-26-000006-index.html0001294192-26-000005
Document: 0001246842-26-000006.txt0001294192-26-000005

US Market Status

Market Closed · Opens in 8h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 15, 2026